Results 91 to 100 of about 13,380 (189)

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Frontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano, Antonio M. Risitano, Serena Marotta, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour, Regis Peffault de Latour   +15 more
doaj   +1 more source

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source

Sequential and Concurrent C5 and Neonatal Fc Receptor Inhibition in Prolonged Myasthenic Crisis due to Advanced Invasive Thymoma‐Associated Myasthenia Gravis: A Case Report and Literature Review

Clinical and Experimental Neuroimmunology, Volume 17, Issue 4, November 2026.
ABSTRACT Thymoma‐associated myasthenia gravis (TAMG) is frequently refractory, particularly when complicated by myasthenic crisis in advanced invasive disease. Complement C5 inhibitors and neonatal Fc receptor (FcRn) inhibitors have expanded the treatment of acetylcholine receptor (AChR) antibody‐positive generalized myasthenia gravis; however, their ...
Yuta Kizuka, Yuriko Nakamura, Kensuke Okada, Yu Okubo, Kaoru Kaseda, Hirofumi Toyama, Keisuke Asakura, Atsuya Takeda, Jin Nakahara, Kei Ishizuchi   +9 more
wiley   +1 more source

Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study

, 2022
Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic syndrome (aHUS). However, the optimal duration of treatment is not clearly defined.
Fidan, Kibriya, CANPOLAT, NUR, Baskin, Esra, Soylemezoglu, Oguz, Gulleroglu, Kaan, ÖZÇAKAR, ZEYNEP BİRSİN, ÖZALTIN, FATİH, Parmakiz, Gonul, Yilmaz, Alev, GÜLHAN, BORA, Fatih Ozaltin, Oguz Soylemezoglu, Kaan Gulleroglu, Nur Canpolat, Kibriya Fidan, Gonül Parmakiz, Zeynep Birsin Özçakar, Alev Yilmaz, Bora Gulhan, Esra Baskin   +19 more
core   +1 more source

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen   +4 more
doaj   +1 more source

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients

Frontiers in Immunology, 2019
Background: Eculizumab blocks the lytic complement pathway by inhibiting C5 and has become the standard of care for certain complement-mediated diseases.
Markus J. Harder, Britta Höchsmann, Britta Höchsmann, Arthur Dopler, Markus Anliker, Christof Weinstock, Christof Weinstock, Arne Skerra, Thomas Simmet, Hubert Schrezenmeier, Hubert Schrezenmeier, Christoph Q. Schmidt   +11 more
doaj   +1 more source

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj   +1 more source

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

Frontiers in Pediatrics
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement ...
Xin Wei, Xinzhu Liu, Yingying Yu, Wei Xie, Wentao Luo, Ye Tu, Shuhong Bu, Guimei Guo   +7 more
doaj   +1 more source

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Case Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro, Carmen Peralta Roselló, Borja Quiroga, José María Baltar Martín, Lorena Castillo Eraso, Fernando de Álvaro Moreno, Alberto Martínez Vea, María Teresa Visus-Fernández de Manzanos   +7 more
doaj   +1 more source

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

, 2016
Fatimah Al-Ani,1 Ian Chin-Yee,1 Alejandro Lazo-Langner1,2 1Department of Medicine, Division of Hematology, 2Department of Epidemiology and Biostatistics, Western University, London, ON, Canada Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a ...
Chin-Yee I, Lazo-Langner A, Al-Ani F
core